Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Epirubicin

Epirubicin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Epirubicin

26 trials tracked of Epirubicin: 10 in phase 3 or 4 and 6 with published results. The most-cited published study has 345 citations.

26Trials tracked
10Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 3 10 Phase 2 15 Phase 1 1
  1. Phase 3 A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer Completed · 345 cited
  2. Phase 3 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Completed · 74 cited
  3. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 64 cited
  4. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 26 cited
  5. Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer Completed · 10 cited
  6. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
Show 20 more trials
  1. Phase 3 Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer Completed
  2. Phase 3 Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer Completed
  3. Phase 3 Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer Completed
  4. Phase 3 Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Completed
  5. Phase 2 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed
  6. Phase 2 Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer Completed
  7. Phase 2 Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer Completed
  8. Phase 2 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Completed
  9. Phase 2 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients Completed
  10. Phase 2 Phase II Trial for Large ER-Negative Breast Cancers Completed
  11. Phase 2 Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer Completed
  12. Phase 2 Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer Completed
  13. Phase 2 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach Completed
  14. Phase 2 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Completed
  15. Phase 2 Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients Completed
  16. Phase 2 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Completed
  17. Phase 2 A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer Completed
  18. Phase 2 Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 Completed
  19. Phase 2 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed
  20. Phase 1 Phase I Combination w/ Epirubicin Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report review of VMAT, utidelone, and denosumab in a breast cancer patient with clivus metastasis
Drug Pipeline Sys. Review
Case report review of VMAT, utidelone, and denosumab in a breast cancer patient with clivus metastasis Rare Breast Cancer Skull Case Achieves Long-Term Remission With New Plan
This case report review describes a single breast cancer patient with clivus metastasis treated with volumetric modulated arc therapy (VMAT)…
A rare case of breast cancer spreading to the skull shows long-term remission using a specific drug and radiation plan.
Frontiers Apr 24, 2026
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
Urology RCT
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer A Common Bladder Cancer Treatment Extends Remission, But at a Cost
This randomized controlled trial compared adjuvant intravesical BCG and Epirubicin in 122 patients with intermediate-risk non-muscle invasiv…
For a common bladder cancer, one treatment keeps the disease away longer, but the other may offer a better daily life.
Apr 12, 2026